Clinical comparative study of liraglutide and benaglutide in adjuvant treatment of T2DM patients complicated with nonalcoholic fatty liver disease
10.3760/cma.j.issn.1008-6706.2020.19.006
- VernacularTitle:利拉鲁肽与贝那鲁肽辅助治疗2型糖尿病伴非酒精性脂肪肝的临床对比研究
- Author:
Xuemei SHE
1
;
Peiwen TIAN
Author Information
1. 山西省，大同市第五人民医院内分泌科 037009
- From:
Chinese Journal of Primary Medicine and Pharmacy
2020;27(19):2329-2333
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To compare the clinical effects of liraglutide and benaglutide in adjuvant treatment of type 2 diabetes mellitus (T2DM) patients complicated with nonalcoholic fatty liver disease (NAFLD).Methods:From January 2017 to January 2019, 110 T2DM patients complicated with NAFLD were chosen in the Fifth People's Hospital of Datong and divided into two groups according to the random digital table method, with 55 patients in each group.On the basis of metformin, the control group was given liraglutide, and the observation group was given benaglutide.The levels of BMI, waist circumference, fasting blood glucose(FPG), postprandial 2h blood glucose(2 h PG), glycosylated hemoglobin(HbA1c), fasting insulin(FINS) release level, insulin resistance index(HOMA-IR), total cholesterol(TC), triglyceride(TG), low density lipoprotein cholesterol(LDL-C), high density lipoprotein cholesterol(HDL-C), levels of glutamate aminotransferase(ALT), aminotransferase(AST), controlled attenuation parameter(CAP) and liver stiffness(LSM) before and after treatment of the two groups were compared.Results:After treatment, the levels of BMI, waist circumference, FBG, 2 h PG, HbA1c, FINS, HOMA-IR, lipid index, ALT, AST, CAP and LSM of the two groups were significantly better than those before treatment( t=3.17, 3.80; 4.95, 5.66; 3.41, 3.50; 3.85, 5.06; 4.43, 4.60; 3.55, 4.17; 3.91, 4.07; 3.26, 3.59; 4.10, 5.27; 4.01, 4.89; 3.62, 3.20; 3.97, 4.62; 4.01, 5.37; 4.66, 5.13; 4.95, 5.87; all P<0.05). After treatment, the levels of BMI, waist circumference, 2 h PG, ALT, AST, CAP and LSM of the control group were (22.01±0.98)kg/m 2, (1.63±0.38)cm, (7.04±1.71)mmol/L, (39.31±4.92)U/L, (31.40±4.94)U/L, (197.48±36.39)dB/m, (7.42±1.34)kPa, respectively, which were significantly worse than those of the observation group [(19.87±0.76)kg/m 2, (0.89±0.21)cm, (6.29±1.10)mmol/L, (36.17±3.16)U/L, (28.63±3.59)U/L, (152.77±30.18)dB/m, (6.17±1.06)kPa] ( t=2.74, 3.55, 2.81, 3.02, 2.76, 2.89, 3.15, all P<0.05). Conclusion:Compared with liraglutide, benaglutide in adjuvant treatment of T2DM patients complicated with NAFLD can efficiently decrease body weight, improve postprandial blood sugar levels, protect liver function and is helpful to inhibit liver fat deposition.
